Sabby Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sabby Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-757	Closed	-$1.05M	–	162
2020 Q4	$1.05M	Buy	+757	New	+$11K	0.2%	49

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Sabby Management's AUPH Position: Q2 2021 in Review

Sabby Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 85,625 shares — an estimated $1.09M sold.

Sabby Management first reported a position in AUPH in Q1 2020 and held it in 5 quarters. The position peaked at $1.11M in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

Sabby Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Sabby Management sold 85,625 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $1.09M.
Sabby Management first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 5 quarters.
Sabby Management's Aurinia Pharmaceuticals position peaked at $1.11M in Q1 2021.
167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.